Pharmacokinetic modelling and validation of the half‐life extension needed to reduce the burden of infusions compared with standard factor <scp>VIII</scp>

Abstract

Based on this investigation, EHL rFVIII products should have a minimum half-life extension ratio of 1.3 to provide a reduction in dosing frequency from 3× to 2×/wk compared with standard rFVIII products while maintaining the same minimum FVIII trough level.